alexa A Real-world Study To Assess The Effectiveness Of Itolizumab In Patients With Chronic Plaque Psoriasis | 60722
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

International Conference on Psoriasis and Skin Specialists Meeting
December 08-09, 2016 Dallas, USA

Anchala Parthsarathy, Swaroop H S, Vinay Singh, Parasramani and Krupashankar D S
Dr. Anchala’s Skin Clinic, India
Biocon Limited, India
Max Healthcare, India
Leelavati Hospital, India
Mallige Hospital, India
ScientificTracks Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554.C1.050
Abstract
Background: The concepts of clinical trial efficacy and real-life effectiveness are both important aspects of clinical decision making. Systematic assessment of real-life effectiveness can lend an evidence-based premise for individualization of treatment options. Realworld data on the anti-psoriatic effectiveness of Itolizumab is relatively scanty. Aims: The specific aims of this study were to assess safety and efficacy of Itolizumab therapy in patients with moderate to severe chronic plaque psoriasis. Methods: A retrospective analysis was conducted at three Indian centers between January 2014 to January 2015 to evaluate the long term safety and efficacy of Itolizumab in patients with moderate to severe chronic plaque psoriasis. At these three centers, 135 patients were prescribed Itolizumab in a dose of 1.6 mg/kg every 2 weeks for first 12 weeks followed by 1.6 mg/kg every 4 weeks up to 24 weeks. The study assessed treatment compliance, improvements in PASI scores and DLQI scores at week 12 and week 24 along with safety and tolerability assessments. Statistical analysis involved descriptive statistics and paired t-test. Results: Out of the 135 patients in the study, 40 (29.62%) received Itolizumab for 12 weeks and 23 (17.03%) patients completed the full Itolizumab regimen. The mean percent change in PASI scores at week 12 and week 24 was 75.16 (p<0.001) and 86.52 (p<0.001), respectively. Furthermore, the mean percent change in DLQI scores at week 12 and week 24 were 60.19 and 82.72, respectively. Adverse events were generally of mild to moderate severity. Limitations: Although Itolizumab therapy is safe and associated with significant improvements in PASI and DLQI scores, compliance to full treatment regimen is around 29.62%. Reasons for this low-compliance are not clear and may need additional studies. Conclusions: Itolizumab is associated with significant improvements in PASI and DLQI scores after ≥12 weeks of treatment. Only about 29.62% and 17.03% patients completed week 12 and week 24 visits respectively. Considering that adverse events were generally of mild to moderate severity, factors other than safety may be contributing to adherence. Understanding these factors may help tailor treatment plans that ensure appropriate adherence.
Biography

Anchala Parthasardhi has completed his MD in Dermatology from Guntur Medical College, Andhra University, India. Currently he is working as the Director of Anchala’s Skin Institute, Hyderabad, India. He has worked as the Head of Department of Dermatology at Image Hospital and successfully guided DNB students in dermatology. He has presented more than 20 papers in national and international conferences and published more than 5 articles in PubMed indexed national and international journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version